[1]辛荣超 郑宇△ 党建军 郑勇 李强 贾承明.藤黄健骨胶囊联合中药湿热敷治疗经皮椎体后凸成形术术后残余腰痛的临床观察[J].中国中医骨伤科杂志,2021,29(10):13-16.
　XIN Rongchao ZHENG Yu DANG Jianjun ZHENG Yong LI Qiang JIA Chengming.Clinical Observation of Tenghuang Jiangu Capsules Combined withWet Hot Compress of Traditional Chinese Medicine in Treatment ofResidual Back Pain after Percutaneous Kyphoplasty[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2021,29(10):13-16.
点击复制

藤黄健骨胶囊联合中药湿热敷治疗经皮椎体后凸成形术术后残余腰痛的临床观察()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第29卷
期数:
2021年10期
页码:
13-16
栏目:
临床研究
出版日期:
2021-10-15

文章信息/Info

Title:
Clinical Observation of Tenghuang Jiangu Capsules Combined withWet Hot Compress of Traditional Chinese Medicine in Treatment ofResidual Back Pain after Percutaneous Kyphoplasty
文章编号:
1005-0205(2021)10-0013-04
作者:
辛荣超1 郑宇1△ 党建军1 郑勇1 李强1 贾承明1
1陕西省中医医院骨伤一科(西安,710003)
Author(s):
XIN Rongchao1 ZHENG Yu1△ DANG Jianjun1 ZHENG Yong1 LI Qiang1 JIA Chengming1
1The First Department of Orthopedics and Traumatology, Shaanxi Provincial Hospital of Chinese Medicine, Xi’an 710003,China.
关键词:
经皮椎体后凸成形术;  残余腰痛;  中药湿热敷;  藤黄健骨胶囊;  疗效
Keywords:
percutaneous kyphoplasty(PKP);  residual back pain;  wet hot compress of traditional Chinese medicine;  Tenghuang Jiangu capsules;  clinical efficacy
分类号:
R681.5
文献标志码:
A
摘要:
目的:观察藤黄健骨胶囊联合中药湿热敷治疗骨质疏松椎体压缩骨折(OVCF)经皮椎体后凸成形术(PKP)术后残余性腰背痛的临床疗效。方法:选取PKP术后残余性腰背痛患者66例,将其随机分为对照组和观察组(各33例),在抗骨质疏松基础治疗的基础上,对照组予中药湿热敷治疗,观察组加服藤黄健骨胶囊,两组患者均治疗4周。比较两组患者VAS疼痛评分、ODI评分、腰椎JOA 评分、血清疼痛物质(SP、NGF、NPY)水平,记录不良反应。结果:治疗后,与对照组比较,观察组VAS、ODI评分,血清 SP、NGF、NPY 水平明显较低,JOA评分明显较高,差异有统计学意义(P<0.05)。两组不良反应发生率相近。结论:藤黄健骨胶囊联合中药湿热敷治疗PKP术后残余性腰痛安全有效,值得临床推广应用。
Abstract:
Objective:To observe the clinical efficacy of Tenghuang Jiangu capsules combined with wet hot compress of traditional Chinese medicine to treat residual back pain after percutaneous kyphoplasty(PKP)in patients with osteoporotic vertebral compression fracture(OVCF). Methods:66 cases after percutaneous kyphoplasty(PKP)were selected and randomly divided into control group(33 cases)and study group(33 cases). On the basis of anti-osteoporosis basic treatment, the control group received the wet hot compress of traditional Chinese medicine, and the study group took Tenghuang Jiangu capsules additionally. All treatment for 4 weeks. VAS score, ODI score, JOA score and serum levels of pain substances(SP, NGF, NPY)were compared, and adverse reactions were recorded. Results:After treatment, compared with the control group, the VAS score, ODI score, the levels of SP, NGF, NPY in serum in study group decreased significantly,JOA score increased significantly in study group(P<0.05). The occurrence rate of adverse reactions was similar. Conclusion:Tenghuang Jiangu capsules combined with wet hot compress of traditional Chinese medicine is safe and effective to treat residual back pain after PKP, and is worth being widely used in clinic.

参考文献/References:

[1] LEE B G,CHOI J H,KIM D Y,et al.Risk factors for newly developed osteoporotic vertebral compression fractures following treatment for osteoporotic vertebral compression fractures[J].Spine J,2019,19(2):301-305.
[2] QI Y,ZENG Y,JIANG C,et al.Comparison of percutaneous kyphoplasty versus modified percutaneous kyphoplasty for treatment of osteoporotic vertebral compression fractures[J].World Neurosurg,2019,122:e1020-e1027.
[3] HE S,ZHANG Y,LV N,et al.The effect of bone cement distribution on clinical efficacy after percutaneous kyphoplasty for osteoporotic vertebral compression fractures[J].Medicine(Baltimore),2019,98(50):e18217.
[4] GUO Z,YANG J,ZHENG Y,et al.Thoracolumbar fascia injury associated with residual back pain after percutaneous vertebroplasty:a compelling study[J].Osteoporos Int,2015,26(11):2709-2710.
[5] YANG J S,LIU J J,CHU L,et al.Causes of residual back pain at early stage after percutaneous vertebroplasty:a retrospective analysis of 1,316 cases[J].Pain Physician,2019,22(5):E495-E503.
[6] 曹辉,周霖,孙志.基于UHPLC-Q-Orbitrap HRMS结合整合网络药理学的藤黄健骨胶囊化学成分识别及作用机制初步研究[J].中草药,2020,51(9):2408-2417.
[7] LI Y,YUE J,HUANG M,et al.Risk factors for postoperative residual back pain after percutaneous kyphoplasty for osteoporotic vertebral compression fractures[J].Eur Spine J,2020,29(10):2568-2575.
[8] JONES T, MILLER R, STREET J T,et al.Validation of the Oswestry Disability Index for pain and disability in arthrogryposis multiplex congenita[J].Ann Phys Rehabil Med,2019,62(2):92-97.
[9] TOMINAGA R, SEKIGUCHI M, YONEMOTO K,et al.Establishment of reference scores and interquartile ranges for the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire(JOABPEQ)in patients with low back pain[J].J Orthop Sci,2018,23(4):643-648.
[10] SHI C,ZHANG M,CHENG AY,et al.Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly[J].Clin Interv Aging,2018,13:853-861.
[11] CHHABRA H, MALHOTRA R, MARWAH S,et al.An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives:an indian subpopulation analysis[J].Indian J Endocrinol Metab,2015,19(4):483-90.
[12] LIU B,GAN F,GE Y,et al.Clinical efficacy analysis of percutaneous kyphoplasty combined with zoledronic acid in the treatment and prevention of osteoporotic vertebral compression fractures[J].J Invest Surg,2018,31(5):425-430.
[13] YE L Q,LIANG D,JIANG X B,et al.Risk factors for the occurrence of insufficient cement distribution in the fractured area after percutaneous vertebroplasty in osteoporotic vertebral compression fractures[J].Pain Physician,2018,21(1):E33-E42.
[14] 黄琛,黄浩,艾志,等.补肾活血汤联合经皮锥体成形术对老年骨质疏松性椎体压缩性骨折的疗效及其安全性观察[J].中华中医药学刊,2018,36(3):719-722.
[15] 朱兴恭.临床正骨学[M].西安:陕西人民出版社,1959:17-18.
[16] 刘军,卢靖雯.藤黄健骨胶囊治疗膝骨关节炎合并骨质疏松症临床分析[J].辽宁中医杂志,2020,47(6):105-107.
[17] 朱蜀云,马素英.藤黄健骨胶囊联合温针灸治疗原发性骨质疏松症的临床研究[J].中国中医骨伤科杂志,2018,26(1):29-33.
[18] ZIEGLG?NSBERGER W.Substance P and pain chronicity[J].Cell Tissue Res,2019,375(1):227-241.
[19] MONTELEONE F, NICOLETTI C G, STAMPANONI BASSI M,et al.Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain[J].J Neuroimmunol,2018,314:89-93.
[20] DIAZ-DELCASTILLO M, WOLDBYE D P D, HEEGAARD A M.Neuropeptide Y and its involvement in chronic pain[J].Neuroscience,2018,387:162-169.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(82060872)
陕西省中医药管理局共建类项目(2019-GJ-JC011)
长安朱氏骨伤流派传承工作室项目(陕中医药发〔2018〕40号)
△通信作者 E-mail:sxszyyygsk@163.com
更新日期/Last Update: 1900-01-01